A Phase 2/3 Study Investigation the Phamacokinetics, Saf

Project: Research project

Description

A Phase 2/3 Study Investigation the Phamacokinetics, Safety and Efficacy of Dupilumab in Patients ages >6 months to <6 years with Severe Atopic Dermatitis
StatusActive
Effective start/end date2/1/172/28/23

Funding

  • Regeneron Pharmaceuticals, Inc.

Fingerprint

Atopic Dermatitis
Safety
SAR231893